A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
- 5 July 2019
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (9) , 2313-2323
Abstract
The optimal treatment in the third-line and later-line setting for metastatic colorectal cancer (mCRC) has not been established. As reported, regorafenib and fruquintinib have shown to be superior to placebo in mCRC. However, no direct clinical comparison of regorafenib and fruquintinib has been conducted; we performed a systematic review and network meta-analysis to compare the efficacy and safety of regorafenib and fruquintinib.Keywords
Funding Information
- National Natural Science Foundation of China (81803569)
This publication has 31 references indexed in Scilit:
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Network Meta-Analysis Using R: A Review of Currently Available Automated PackagesPLOS ONE, 2014
- Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapyCancer Biology & Therapy, 2014
- Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokineticsCancer Chemotherapy and Pharmacology, 2014
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Oncology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication biasJournal of Cranio-Maxillofacial Surgery, 2011
- Simultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ, 2005